Since EGFR-L858R mutant frequently (approximately 35–45%) appears in NSCLC patients [12], we chose H1299-EGFR-L858R stable cells to further characterize the interaction with AURKA. This evidence concerns the gene EGFR and non-small cell lung carcinoma.